[Hemostatic disorders with secretolytics? A contribution to drug safety].
Based on literature and on the results of this open clinical trial we conclude, that there is no connection between application of the above named group of drugs and the change in parameters of haemostasis function, which might lead to a manifest haemorrhagic diathesis. Within the period surveyed of 14 days no case of induced coagulopathy and particularly no thrombocytopenia was seen. The substances under consideration themselves did not exert any anticoagulatory effect nor did they potentiate or inhibit the effect of a concurrently given cumarin derivative.
D000551:Ambroxol / Q000009:adverse effects; D001777:Blood Coagulation / Q000187:drug effects; D001964:Bromhexine / Q000009:adverse effects*; D004338:Drug Combinations; D006474:Hemorrhagic Disorders / Q000139:chemically induced*; D006801:Humans; D010118:Oxytetracycline; D013921:Thrombocytopenia / Q000139:chemically induced
D004338:Drug Combinations; D000551:Ambroxol; D001964:Bromhexine; D010118:Oxytetracycline
Hämosasestörungen bei Sekretolytika? Ein Beitrag zur Arzneimittelsicherheit